Please login to the form below

Not currently logged in
Email:
Password:

Sam Agus takes up new role at Hansa Medical

Will focus on the firm’s lead kidney transplantation project IdeS

Hansa Medical has appointed Sam Agus as it’s new chief medical officer, a role that will see him focus on building an effective company strategy around the global market for the launch of IdeS – a project based on kidney transplants in sensitised patients.

Agus has previously held various leading positions at several pharmaceutical companies including Shire, Solvay Pharmaceuticals, Abbott Laboratories and most recently at H.Lundbeck A/S as it’s chief specialist, medical affairs neurology.

With experience in medical strategy, multidisciplinary team leadership, medical marketing and clinical trial design, Agus’s therapy area expertise includes neurology, psychiatry, gastroenterology, women’s health and rare diseases.

Göran Arvidson, president and CEO of Hansa Medical, said: “We are very pleased to have Sam joining our team in this truly exciting phase for Hansa Medical.

“His experience from building and leading strong teams will be a central part in our next phase towards commercialisation of IdeS.”

Sam Agus succeeds Steven Glazer who will continue to provide strategic advice to Swedish biopharmaceutical firm Hansa.

4th April 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics